68818 Federal Register / Vol. 71, No. 228 / Tuesday, November 28, 2006 / Notices 

liquidity, credit, and operational risks 

related to Fedwire funds transfers, 

especially late-day transfers. The paper 

also requested views on potential 

changes in market practices, operations, 

and the Board’s Payments System Risk 

policy that could reduce one or more of 

these risks. The consultation paper 

stated that comments must be submitted 

on or before December 15, 2006. 

The Board received a letter from an 

industry group, whose members include 

a number of large U.S. depository 

institutions and foreign banking 

organizations, requesting, on behalf of 

that group and its members, an 

extension of the comment period. Based 

on interactions the Board has had with 

this group, its members, and other 

interested parties, the Board believes 

that an extension would enable these 

organizations to investigate further the 

drivers of their liquidity management 

practices and late-day Fedwire funds 

transfers. The extension will also allow 

a range of organizations more time to 

provide a thorough response to the 

consultation paper. Consequently, the 

Board has decided to extend the 

comment period on the consultation 

paper by 90 days. The comment period 

will now end March 15, 2007. 

By order of the Board of Governors of the 

Federal Reserve System, acting through the 

Secretary of the Board under delegated 

authority, November 21, 2006. 

Jennifer J. Johnson, 

Secretary of the Board. 

[FR Doc. E6–20048 Filed 11–27–06; 8:45 am] 

BILLING CODE 6210–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the National Coordinator for 

Health Information Technology; 

American Health Information 

Community Meeting 

ACTION: Announcement of meeting. 

SUMMARY: This notice announces the 

tenth meeting of the American Health 

Information Community in accordance 

with the Federal Advisory Committee 

Act (Pub. L. No. 92–463, 5 U.S.C., App.) 

The American Health Information 

Community will advise the Secretary 

and recommend specific actions to 

achieve a common interoperability 

framework for health information 

technology (IT). 

DATES: December 12, 2006, from 8:30 

a.m. to 12 p.m. 

ADDRESSES: Hubert H. Humphrey 

building (200 Independence Avenue, 

SW., Washington, DC 20201), 

Conference Room 800. 

FOR FURTHER INFORMATION CONTACT: Visit 

http://www.hhs.gov/healthit/ahic.html. 

SUPPLEMENTARY INFORMATION: The 

Community will discuss state-federal 

health information exchange technology 

and coordination, the development of 

proto-use cases, and an update on the 

Personalized Healthcare Workgroup. 

A Web cast of the Community 

meeting will be available on the NIH 

Web site at: http:// 

www.videocast.nih.gov/. 

If you have special needs for the 

meeting, please contact (202) 690–7151. 

Dated: November 16, 2006. 

Judith Sparrow, 

Director, American Health Information 

Community, Office of Programs and 

Coordination, Office of the National 

Coordinator for Health Information 

Technology. 

[FR Doc. 06–9430 Filed 11–27–06; 8:45 am] 

BILLING CODE 4150–24–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Proposed Information Collection 

Activity; Comment Request 

Proposed Projects: 

Title: Annual Maintenance-of-Effort 

(MOE) Report. 

OMB No.: 0970–0248. 

Description: The Administration for 

Children and Families (ACF) is 

requesting a three-year extension of the 

ACF–204 (Annual MOE Report). The 

report is used to collect descriptive 

program characteristics information on 

the programs operated by States and 

Territories in association with their 

Temporary Assistance for Needy 

Families (TANF) programs. All State 

and Territory expenditures claimed 

toward States’ and Territories’ MOE 

requirements must be appropriate, i.e., 

meet all applicable MOE requirements. 

The Annual MOE Report provides the 

ability to learn about and to monitor the 

nature of State and Territory 

expenditures used to meet State’s and 

Territories’ MOE requirements, and it is 

an important source of information 

about the different ways that States and 

Territories are using their resources to 

help families attain and maintain selfsufficiency. In addition, the report is 

used to obtain State and Territory 

program characteristics for ACF’s 

annual report to Congress, and the 

report serves as a useful resource to use 

in Congressional hearings about how 

TANF programs are evolving, in 

assessing State and Territory MOE 

expenditures, and in assessing the need 

for legislative changes. 

Respondents: The 50 States of the 

United States, the District of Columbia, 

Guam, Puerto Rico, and the Virgin 

Islands. 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden hours 

per response 

Total burden 

hours 

ACF–204 .......................................................................................................... 54 1 128 6,912

Estimated Total Annual Burden 

Hours: 6,912. 

In compliance with the requirements 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995, the 

Administration for Children and 

Families is soliciting public comment 

on the specific aspects of the 

information collection described above. 

Copies of the proposed collection of 

information can be obtained and 

comments may be forwarded by writing 

to the Administration for Children and 

Families, Office of Administration, 

Office of Information Services, 370 

L’Enfant Promenade, SW., Washington, 

DC 20447, Attn: ACF Reports Clearance 

Officer. E-mail address: 

rsargis@acf.hhs.gov. All requests should 

be identified by the title of the 

information collection. 

The Department specifically requests 

comments on: (a) Whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information shall have 


ycherry on PROD1PC61 with NOTICES
Federal Register / Vol. 71, No. 228 / Tuesday, November 28, 2006 / Notices 68819 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

the quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Consideration will be given to 

comments and suggestions submitted 

within 60 days of this publication. 

Dated: November 21, 2006. 

Robert Sargis, 

Reports Clearance Officer. 

[FR Doc. 06–9413 Filed 11–27–06; 8:45 am] 

BILLING CODE 4184–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. 2006N–0465] 

Improving Patient Safety by Enhancing 

the Container Labeling for Parenteral 

Infusion Drug Products; Public 

Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of public meeting; 

request for comments. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing a 

public meeting on improving patient 

safety by enhancing the container 

labeling for parenteral infusion drug 

products. This will be a 1-day workshop 

involving FDA staff and representatives 

of the United States Pharmacopeia 

(USP) and the Institute for Safe 

Medication Practices (ISMP). The 

purpose of the meeting is to explore 

how labels on intravenous (IV) drug 

products could be designed to minimize 

medication errors. Design issues include 

placement, style and type of 

information, the need for standard 

expression of strength, quantity of 

information, and use of color on the 

label. 

DATES: The public meeting will be held 

on January 11, 2007, from 8 a.m. to 4 

p.m. Submit written or electronic 

requests to speak by December 28, 2006. 

Written or electronic comments to the 

docket will be accepted until April 12, 

2007. 

ADDRESSES: The public meeting will be 

held at the Lister Hill Center 

Auditorium (the center), National 

Institutes of Health (NIH) campus, 9000 

Rockville Pike, bldg. 38A, Bethesda, MD 

20815, 301–496–4441. The center can be 

reached by Metro using the Medical 

Center Station on the red line. Parking 

is limited at NIH, so Metro use is 

recommended. For directions and 

visitor information, see http:// 

www.nih.gov/about/visitor/index.htm. 

(FDA has verified the Web site address, 

but FDA is not responsible for any 

subsequent changes to the Web site after 

this document publishes in the Federal 

Register). 

Submit written comments to the 

Division of Dockets Management (HFA–

305), Food and Drug Administration, 

5630 Fishers Lane, rm. 1061, Rockville, 

MD 20852. Submit electronic comments 

to http://www.fda.gov/dockets/ 

ecomments. Submit written or 

electronic requests to speak at the 

meeting to the information contact. 

Transcripts of the hearing will be 

available for review at the Division of 

Dockets Management and on the 

Internet at http://www.fda.gov/cder/ 

meeting/parenteralllabeling.htm. 

FOR FURTHER INFORMATION CONTACT: Jean 

Chung, Center for Drug Evaluation and 

Research (HFD–400), Food and Drug 

Administration, 5600 Fishers Lane, 

Rockville, MD 20857, 301–796–2380, email: jean.chung@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

I. Background 

Premixed large volume parenterals 

(LVPs) and small volume parenterals 

(SVPs) in ready to infuse final dosage 

forms are designed to deliver premixed 

drugs (e.g., antibiotics, electrolyte 

solutions, pain management infusions). 

Premixed LVPs and SVPs improve 

standardized drug delivery and can 

reduce the potential for medication 

errors by reducing the steps required in 

IV preparation and the additional 

quality control checks needed by the 

pharmacy prior to dispensing and 

administering the product. Premixed 

LVPs and SVPs: (1) Provide an end 

product that is labeled with the 

ingredients including a product 

identification code (e.g., bar code), (2) 

promote a sterile environment, and (3) 

maintain accurate concentration within 

a closed system. According to the USP, 

‘‘the designation large-volume 

intravenous solution applies to a singledose injection that is intended for 

intravenous use and is packaged in 

containers labeled as containing more 

than 100 mL. The designation smallvolume injection applies to an injection 

that is packaged in containers labeled as 

containing 100 mL or less.’’

Although premixed LVPs and SVPs 

can reduce the potential for mixing 

errors, the labels and labeling of these 

products, as well as base solutions of 

LVPs and SVPs without drug, have been 

documented as contributing to 

medication errors in both acute care and 

ambulatory settings, as well as in home 

care settings. The types of errors 

reported involve the inability to 

distinguish different drug products, as 

well as different strengths of drug 

products, because the containers look 

similar and use similar colors for label 

text. In addition to these visual 

similarities, manufacturers may label 

the same drug product with varying 

units of measure (e.g., micrograms 

versus milligrams), which has also 

contributed to error. There is also a large 

amount of information that is placed on 

the container label that can not only 

crowd the label but can distract from the 

most important information, that is, the 

proprietary and established names and 

product strength.Thus, we would like to 

explore how current IV labels should be 

designed to minimize medication errors. 

II. Scope of the Public Meeting 

The public meeting is intended to 

explore how IV labels could be designed 

to minimize medication errors. Design 

issues include placement, style and type 

of information, the need for standard 

expression of strength, quantity of 

information, and use of color on the 

label. 

This 1-day workshop will assemble 

drug safety experts, patient advocates, 

government experts, and 

pharmaceutical and device 

manufacturers to discuss outstanding 

regulatory, technological, and resource 

issues. Other interested constituencies 

(e.g., patient advocacy and education 

groups, pharmaceutical sponsors, 

general public) will have an opportunity 

to provide input during the question 

and comment periods. FDA is interested 

in obtaining public comment and 

encourages all interested parties to 

submit requests to speak at the meeting 

or to submit written or electronic 

comments to the docket. (See sections 

III. and IV. of this document.) 

The meeting will include an overview 

of FDA and USP requirements, 

presentations from the clinical 

perspective (nurse and pharmacist) and 

industry perspective, and a series of 

panel discussions. The following topics 

will be discussed: Look-alike containers, 

confusing labels on sterile water 

containers, container label 

requirements, and the lack of 

standardized expression of medication 

concentration on labels. Questions that 

will be considered during this public 

meeting include, but are not limited to, 

the following: 

1. What are the best solutions to 

differentiate look-alike container labels 


ycherry on PROD1PC61 with NOTICES